Search result
August 2023: $$ Integrative proteomics highlight presynaptic alterations and c-Jun misactivation as convergent pathomechanisms in ALS
Journal: Acta Neuropathologica 2023
Author: Dr. Alberto Catanese
Institution: Universität Ulm, Institut für Anatomie und Zellbiologie
July 2023: $$ GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response
Journal: Brain 2023
Author: Matthis Synofzik
Institution: Center for Neurology and Hertie Institute for Clinical Brain Research Tübingen
June 2023: $$ The RNA editor ADAR2 promotes immune cell trafficking by enhancing endothelial responses to interleukin-6 during sterile inflammation
Journal: Immunity 2023
Authors: Aikaterini Gatsiou und Konstantinos Stellos
Institution: Newcastle University and Universität Heidelberg
Non-Communicable Diseases
To improve the health of people afflicted with NCDs in resource-limited countries, EKFS launched a special call for proposals aimed at this thematic priority for the first time in 2022.
Program: 4th Interdisciplinary Network Symposium for and by Clinician Scientists
Organizer: Dean’s Office for Academic Career Development and Clinician Scientist Program at the MHH University Hospital Hannover
EKFS panel “Innovative Academic Cooperations ─ Partnerships to improve health”
World Health Summit 2023
Else Kröner Memorial Fellowships 2023
EKFS facilitates excellence in tomorrow’s medicine and awards nine fellowships to particularly talented young physicians.
Checking back: What is Dr. Leonhard Möckl, successful first-round and second-time applicant from 2020, doing these days?
In our series Checking back, today we are introducing you to Dr. Leonhard Möckl. Since 2020 the chemist has been an independent group leader at the Max Planck Institute for the Science of Light (MPL) in Erlangen, Germany. EKFS has funded his project toward developing new strategies in cancer therapy since 2020.